Teladoc Health, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Teladoc Health, Inc. on August 3, 2026. The report discloses corporate governance changes effective as of the filing date.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on board composition and does not contain financial performance data.
Material Changes
- Board Expansion: The Board of Directors increased the number of directors from nine to ten.
- New Appointment: Mark V. Anquillare was appointed as a director.
- Committee Assignments: Mr. Anquillare was appointed to both the Audit Committee and the Compensation Committee.
- Independence Status: The Board determined Mr. Anquillare is an independent director and an "audit committee financial expert" under SEC and NYSE rules.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding business performance. No new risks or contingencies were disclosed in this report. The appointment is subject to standard director indemnification arrangements and eligibility for non-employee director compensation programs as described in the Company's Proxy Statement filed on April 7, 2026.
Key Facts for Investor Verification
- Verify Mark V. Anquillare's professional background and qualifications as an audit committee financial expert.
- Review the Company's Proxy Statement filed on April 7, 2026, for details on non-employee director compensation programs.
- Confirm the total number of directors on the Board is now ten.
- Note that this filing does not impact the Company's financial statements or operational metrics.